Specific proteoglycans as potential causative agents and relevant targets for therapeutic intervention in Alzheimer's disease and other amyloidosis

Amyloid

Volumn 4, Issue 2, 1997, Pages 135-141

  Snow, Alan D ^a   Castillo, Gerardo M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000416462     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129708995283     Document Type: Editorial

References (50)

1. Snow A D, Kisilevsky R. A temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study. Lab Invest 1985; 53: 37 – 44
2. Snow A D, Kisilevsky R, Willmer J. A close ultra-structural relationship between sulphated proteoglycans and AA amyloid fibrils. Lab Invest 1987; 57: 687 – 698
3. Snow A D, Wight T N, Mar H, Bramson R, Kisilevsky R. A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 1991; 39: 1321 – 1330
4. Snow A D, Willmer J, Kisilevsky R. Sulphated glycosaminoglycans: A common constituent of all amyloids?. Lab Invest 1987; 56: 120 – 123
5. Snow A D, Kisilevsky R, Willmer J, Prusiner S B, DeArmond S J. Sulphated glycosaminoglycans in amyloid plaques in prion diseases. Acta Neuropath 1989; 77: 337 – 342
6. Snow A D, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, Wight T N. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Path 1988; 133: 456 – 463
7. Snow A D, Wight T N, Nochlin D, Koike Y, Kimata K, DeArmond S J, Prusiner S B. Immunolocalization of heparan sulfate proteoglycans to prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. Lab Invest 1990; 63: 601 – 611
8. Snow A D, Wight T N. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiology Aging 1989; 10: 481 – 497
9. Snow A D, Mar H, Nochlin D, Sekiguchi R T, Kimata K, Koike Y, Wight T N. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein containing lesions of Alzheimer's disease and Down's syndrome. Am J Path 1990; 137: 1253 – 1270
10. Perlmutter L S, Chui H C, Saperia D, Athanikar J. Microangiopathy and the colocalization of heparan sulfate proteoglycan. Br Res 1990; 508: 13 – 19
11. Su J H, Cummings B J, Cotman C W. Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease. Neurosc 1992; 51: 801 – 813
12. Van Cool D, David D, Lammens M, Baro F, Dom R. Heparan sulfate expression patterns in the amyloid deposits of patients with Alzheimer's disease. Dementia 1993; 4: 308 – 314
13. Snow A D, Mar H, Nochlin D, Kresse H, Wight T N. Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. J Histochem Cytochem 1992; 40: 105 – 113
14. DeWitt D A, Silver J, Canning D R, Perry G. Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp Neurol 1993; 121: 149 – 152
15. Snow A D, Nochlin D, Sekiguchi R, Carlson S. Identification and immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease. Exp Neurol 1996; 138: 305 – 317
16. Snow A D, Sekiguchi R, Nochlin D, Kalaria R N, Kimata K. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not in cerebellum of Alzheimer's disease brain. Am J Path 1994; 144: 337 – 347
17. Snow A D, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mitzutani A, Arai M, Schreier W A, Morgan D G. An important role of heparan sulfate proteoglycans (perlecan) in a model system for the deposition and persistence of fibrillar Aβ amyloid in rat brain. Neuron 1994; 12: 219 – 234
18. Snow A D, Kinsella M G, Prather P B, Nochlin D, Podlisny M B, Selkoe D J, Kisilevsky R, Wight T N. A characteristic binding affinity between heparan sulfate proteoglycans and the A4 amyloid protein of Alzheimer's disease. J Neuropath Exp Neurol 1989; 48, 352 Abstract
19. Buee L, Ding W, Anderson J P, Narindrasorasak S, Kisilevsky R, Boyle N J, Robakis N K, Delacourte A, Greenberg B, Fillit H M. Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide. Br Res 1993; 627: 199 – 204
20. Buee Ding L. W, Delacourte A, Fillit H. Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide. Br Res 1993; 601: 154 – 163
21. Snow A D, Kinsella M G, Parks E, Sekiguchi R T, Miller J D, Kimata K, Wight T N. Differential binding of vascular cell derived proteoglycans (perlecan, biglycan, decorin and versican) to the beta-amyloid protein of Alzheimer's disease. Arch Biochem Biophys 1995; 320: 84 – 95
22. Narindrasorasak S, Lowery D, Gonzalez-DeWhitt P, Poorman R A, Greenberg B, Kisilevsky R. High affinity interactions between the Alzheimer's beta-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J Biol Chem 1991; 266: 12878 – 12883
23. Snow A D, Cummings J A, Ngo C T, Yang W, Nochlin D, Rimvall K, Sheardown M J, Judge M E. Further studies implicating the importance of perlecan (a specific heparan sulfate proteoglycan) in an animal model of fibrillar Aβ amyloid deposition in vivo: comparison of Aβ (1–42) versus Aβ (1–40). Soc Neurosc Abst 1995; 21: 1282
24. Gumpta-Bansal R, Frederickson C A, Brunden K R. Proteoglycan-mediated inhibition of Al3 proteolysis. J Biol Chem 1995; 270: 18666 – 18671
25. Castillo G M, Cummings J A, Ngo C, Yang W, Snow A D. Novel purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm tumor for use in an animal model of fibrillar Aβ amyloid persistence in brain. J Biochem 1996; 120: 433 – 444
26. Castillo G M, Snow A D. Perlecan binds to both beta-amyloid protein (Aβ) 1–40 and 1–42 and is a potent accelerator and enhancer of Aβ fibrillogenesis. Neurobiol Aging 1996; 17, S174 Abstract
27. Castillo G M, Ngo C, Snow A D. Perlecan binding to Alzheimer's disease beta-amyloid protein (AR) 1–40 regardless of the extent of fibrillogenesis. Soc Neurosc Abst 1996; 22: 1172
28. Brunden K R. pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans. J Neurochem 1993; 61: 2147 – 2154
29. Ailles L, Kisilevsky R, Young I D. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest 1993; 69: 443 – 448
30. Goedert M, Jakes R, Spillantini M G, Hasegawa M, Smith M J, Crowther R A. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 1996; 383: 550 – 553
31. Pérez M, Valpuesta J M, Medina M, Montejo de Garcini E, Avila J. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. J Neurochem 1996; 67: 1183 – 1190
32. Kinsella M G, Wight T N. Structural characterization of heparan sulfate proteoglycan subclasses isolated from bovine aortic endothelial cell cultures. Biochem 1988; 27: 2136 – 2144
33. Murdoch A D, Liu B, Schwarting R, Tuan R S, Iozzo R V. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem 1994; 42: 239 – 249
34. Chakravarti S, Hassell J R, Phillips S. Perlecan gene expression precedes laminin gene expression during differentiation of F9 embryonal carcinoma cells. Dev Dyn 1993; 197: 107 – 114
35. Sekiguchi R T, Potter-Perigo S, Braun K, Miller J, Ngo C., Fukuchi K, Wight T N, Kimata K, Snow A D. Characterization of proteoglycans synthesized by murine embryonal carcinoma cells (P19) reveals increased expression of perlecan (heparan sulfate proteoglycan) during neuronal differentiation. J Neurosc Res 1994; 38: 670 – 686
36. Dodge G R, Boesler E W, Jimenez S A. Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells. Lab Invest 1995; 73: 649 – 657
37. Snow A D, Cummings J, Ngo C, Kimata K, Wight T N, Miller J D. Localization of perlecan (or an immuno-logically related proteoglycan) to isolated microglia in vitro and to infiltrating microglia following infusion of beta-amyloid protein into rodent hippocampus. Neurobiol Aging 1996; 17, S156 Abstract
38. Maresh G A, Erezyilmaz D, Murry C E, Nochlin D, Snow A D. Detection and quantitation of perlecan mRNA levels in Alzheimer's disease and normal aged hippocampus by competitive reverse transcription-polymerase chain reaction. J Neurochem 1996; 67: 1132 – 1144
39. Joseph S J, Ford M D, Barth C, Portbury S, Bartlett PF., Nurcombe V, Greferath U. A proteoglycan that activates fibroblast growth factors during early neuronal development is a perlecan variant. Development 1996; 122: 3443 – 3452
40. Fraser P E, Nguyen J T, Chin D T, Kirschner D A. Effects of sulfate ions on Alzheimer's β/A4 peptide assemblies: implications for amyloid-fibril proteoglycan interactions. J Neurochem 1992; 59: 1531 – 1540
41. Kisilevsky R, Lemieux L J, Fraser P E, Kong X, Hultin P G, Szarek W A. Arresting amyloidosis using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nature Med 1995; 1: 143 – 148
42. Caughey B, Brown K, Raymond G J, Katzenstein G E, Thresher W. Binding of the protease-sensitive form of the prion protein PrP to sulfated glycosaminoglycan and Congo red. J Virol 1994; 68: 2135 – 2141
43. Lyon A W, Narindrasorasak S, Young I D, Anastassiades T, Couchman J R, McCarthy K J, Kisilevsky R. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 1991; 64: 785 – 790
44. Ailles L, Kisilevsky R, Young I D. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest 1993; 69: 443 – 448
45. Narindrasorasak S, Lowery D E, Altman R A, Gonzalez-DeWhitt P A, Greenberg B D, Kisilevsky R. High affinity interactions between the Alzheimer's beta-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J Biol Chem 1991; 266: 12878 – 12883
46. Narindrasorasak S, Lowery D E, Altman R A, Gonzalez-De Whitt P A, Greenberg B D, Kisilevsky R. Characterization of high affinity binding between laminin and Alzheimer's disease amyloid precursor proteins. Lab Invest 1992; 67: 643 – 652
47. Narindrasorasak S, Altman R A, Gonzalez-De Whitt P, Greenberg B D, Kisilevsky R. An interaction between basement membrane and Alzheimer's amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease. Lab Invest 1995; 72: 272 – 282
48. Small D H, Nurcornbe V, Clamis H, Beyreuther K, Masters C L. The role of extracellular matrix in the processing of the amyloid protein precursor of Alzheimer's disease. Ann NY Acad Sci 1993; 695: 169 – 174
49. Bronfman F C, Garrido J, Alvarez A, Morgan C, Inestrosa M C. Laminin inhibits amyloid-β-peptide fibrillation. Neurosc Lett 1996; 218: 201 – 203
50. Fukuchi K, Tonunaga T, Hassell J R, Snow A D. Overexpression of perlecan and beta-amyloid protein in transgenic mice. Soc Neurosc 1996; 22, 24 Abstract